natgillin/translations-raw huggingface dataset:
The proportion of subjects with clinically significant weight gain (≥ 7 % weight gain from baseline at endpoint) in the short-term, flexible-dose bipolar mania trials was 6.5 % for asenapine compared to 0.6 % for placebo.
V kratkotrajnih preskušanjih s prilagodljivim odmerkom pri bolnikih z manijo pri bipolarni motnji pa je bil odstotek preiskovancev s klinično pomembnim povečanjem telesne mase (t.j. z ≥ 7 % povečanjem telesne mase pri končnem rezultatu, v primerjavi z začetnimi vrednostmi) 6,5 % za asenapin in 0,6 % za placebo.
The proportion of subjects with HIV-1 RNA < 50 copies/mL at week 48 (TLOVR) was 72.2% (26/36).
Po 48 tednih (TLOVR) je bil delež bolnikov z < 50 kopij/ml 72,2% (26/36).
The proportion of subjects with hSBA ≥ 1:8 was non-inferior to ACWY-PS for all four serogroups and statistically superior for serogroups A and Y (Table 10).
Razmerje oseb s titri hSBA ≥ 1:8 ni bilo inferiorno kot pri ACWY-PS za vse štiri seroskupine, za skupini A in Y pa je bilo statistično boljše (tabela 10).
The proportion was significantly larger than observed with insulin degludec (40.9%, odds ratio 2.28, p < 0.0001) and similar to that observed with liraglutide (57.7%, odds ratio 1.13, p=0.3184).
Delež je bil pomembno večji od deleža pri insulinu degludek (40,9 %, razmerje obetov 2,28, p<0,0001) in podoben deležu pri liraglutidu (57,7 %, razmerje obetov 1,13, p=0,3184).
The proportions of MabThera treated patients showing a minimal clinically important difference (MCID) in HAQ-DI (defined as an individual total score decrease of >0.22) was also higher than among patients receiving methotrexate alone (Table 12).
Tudi delež z zdravilom MabThera zdravljenih bolnikov, pri katerih se je pojavila minimalna klinično pomembna razlika (MCID, Minimal Clinically Important Difference) v HAQ-DI (opredeljena kot zmanjšanje individualne celotne ocene za > 0,22), je bil večji kot pri bolnikih, ki so prejemali samo metotreksat (preglednica 12).
The proportions of patients taking placebo who achieved this goal were 28% and 26% respectively.
Takšen rezultat je v skupini bolnikov, ki je jemala placebo, doseglo 28 % v eni študiji in 26 % bolnikov v drugi.
The proportions of patients with no signs of viral activity in their blood at follow-up were 32% with Pegasys and 22% with lamivudine in the HBeAg-positive patients, and 43% with Pegasys and 29% with lamivudine in the HBeAg-negative patients.
Delež bolnikov brez znakov virusne dejavnosti v krvi ob kontrolnem obisku je bil pri HBeAg pozitivnih bolnikih 32 % pri uporabi zdravila Pegasys oziroma 22 % pri uporabi lamivudina, pri HBeAg negativnih bolnikih pa 43 % pri uporabi zdravila Pegasys oziroma 29 % pri uporabi lamivudina.
The proportions of patients with plasma HIV-1 RNA < 50 copies/mL and < 20 copies/mL are shown in Table 5.
RNA HIV-1 < 50 kopij/ml in < 20 kopij/ml v plazmi sta prikazana v preglednici 5.
The proposed changes to sections 4.6 and 4.8 of the SmPC and the leaflet are detailed in Annex 1 of this assessment report.
Predlagane spremembe poglavij 4.6 in 4.8 povzetka glavnih značilnosti zdravila in navodila za uporabo so podrobno navedene v Prilogi 1 tega poročila o oceni zdravila.
The prospective randomised (UKPDS) study has established the long-term benefit of intensive blood glucose control in type 2 diabetes.
Prospektivne randomizirane raziskave (UKPDS) ugotavljajo dolgoročno korist intenzivne urejenosti glukoze v krvi pri sladkorni bolezni tipa 2.
The prospective randomised (UKPDS) study has established the long-term benefit of intensive blood glucose control in type 2 diabetes.
V prospektivni randomizirani študiji (UKDPS) je bila dokazana dolgoročna korist intenzivnega urejanja glukoze v krvi pri sladkorni bolezni tipa 2.
The prospective randomised UKPDS (UK Prospective Diabetes Study) study has established the long- term benefit of intensive blood glucose control in type 2 diabetes.
V prospektivni randomizirani študiji UKPDS (UK Prospective Diabetes Study - Britanska prospektivna študija diabetesa) so ugotovili dolgoročno koristnost intenzivnega uravnavanja koncentracije glukoze pri diabetesu tipa 2.
The prospective,
registra je
The protection against other circulating IB strains has not been investigated.
Zaščite proti drugim krožečim sevom infekcioznega bronhitisa niso raziskovali.
The protection against pregnancy is not reduced, and you do not need to take extra precautions.
Zaščita pred zanositvijo ni zmanjšana, zato dodatni ukrepi niso potrebni.
The protection given by Ibraxion was measured by the reduction of clinical signs of IBR after the virus was introduced to the cattle.
Merilo zaščite, ki jo daje zdravilo Ibraxion, je bilo merjeno z zmajševanjem kliničnih znakov IBR po tem, ko je bil virus vnesen v govedo.
The protective cap is removed from the injection needle and air is expelled from the syringe and needle by holding the syringe vertically and gently pressing the plunger upwards.
Odstranite zaščito za iglo in pazljivo odstranite zrak iz injekcijske brizge tako, da jo držite navpično, bat pa počasi potiskate navzgor, dokler se na konici igle ne pojavi kapljica tekočine.
The protective vaccine efficacy after two doses of Rotarix observed against severe rotavirus gastro- enteritis up to 2 years of age is presented in the following table:
V spodnji preglednici je prikazana učinkovitost zaščite cepiva po dveh odmerkih cepiva Rotarix, opažena proti hudemu rotavirusnemu gastroenteritisu v starosti do 2 let:
The protein binding of brimonidine has not been studied.
Vezave brimonidina na beljakovine niso preučili.
The protein binding of ritonavir in human plasma is approximately 98 - 99% and is constant over the concentration range of 1.0 – 100 g/ml.
Vezava ritonavirja na beljakovine v človeški plazmi je približno 98-99 % in je v koncentracijskem območju od 1,0 do 100 g/ml stalna.
The protein binding of the major metabolite (a para-hydroxy-sulphate) is very high (> 99.99%).
Stopnja vezave glavnega metabolita (parahidroksisulfata) na proteine je zelo visoka (> 99,99 %).
The protein binding of the major metabolite (para-hydroxy-sulphate) is very high (>99.99%).
Stopnja vezave glavnega presnovka (parahidroksisulfata) na proteine je zelo visoka ( 99,99 %).
The protein is known as epidermal growth factor receptor (EGFR).
To beljakovino poznamo po imenu receptor za epidermalni rastni dejavnik (EGFR- epidermal growth factor receptor).
The protein product of the proto-oncogene RAS (rat sarcoma) is a central down-stream signal- transducer of EGFR.
Beljakovinski produkt protoonkogenega RAS (podganji sarkom) je osrednji prevodnik signala faktorja EGFR po signalni poti navzdol.
The proteins are assembled in ‘virus-like particles’ (structures that look like HPV, so that the body can recognise them easily).
Beljakovine tvorijo virusu podobne delce (strukture, ki so podobne humanemu papilomavirusu, tako da jih telo zlahka prepozna).
the protocol
Predložitev protokola do
The protocol of study GAO4753g defined patients with iNHL including FL as the study population.
V protokolu študije GAO4753g so kot študijsko populacijo opredelili bolnike z iNHL, vključno s FL.
The protocol pre-specified interim analysis after 520 deaths showed a statistically significant superiority in overall survival in patients treated with enzalutamide compared to placebo (Table 3 and Figures 4 and 5).
V protokolu vnaprej določena vmesna analiza po 520 smrtih je pri bolnikih, ki so prejemali enzalutamid, pokazala statistično značilno superiornost glede celokupnega preživetja v primerjavi s placebom (preglednica 3 in sliki 4 in 5).
The protocol should be submitted to the Committee for review and agreement promptly, and no later than 3 months after the Commission Decision granting the marketing authorisation, in order to allow for the study to be conducted in the stipulated period.
Protokol je treba takoj predložiti Odboru v pregled in odobritev, vendar ne kasneje kot 3 mesece po sklepu Komisije o odobritvi dovoljenja za promet z zdravilom, da se omogoči izvedba študije v določenem obdobju.
The protocol specified analysis of investigator-assessed PFS (without censoring for CA-125 progression or non-protocol therapy [NPT]) shows a stratified hazard ratio of 0.71 (95% CI: 0.61-0.83, 1-sided log-rank p-value < 0.0001) when CPB15+ is compared with CPP, with a median PFS of 10.4 months in the CPP arm and 14.1 months in the CPB15+ arm.
S protokolom opredeljena analiza preživetja brez napredovanja bolezni, ocenjena s strani raziskovalca (brez krnjenih podatkov za napredovanje bolezni glede na CA 125 ali zdravljenja, ki ni bilo v skladu s protokolom) kaže stratificirano razmerje ogroženosti 0,71 (95-% interval zaupanja: 0,61-0,83; p-vrednost za enostranski log rank test < 0,0001) ko primerjamo CPB15+ s CPP, z mediano preživetja brez napredovanja bolezni 10,4 meseca v CPP skupini in 14,1 meseca v CPB15+ skupini.
The protocol-specified goal was achievement of asparagine depletion to a serum concentration of 1 M.
Cilj, opredeljen v protokolu, je bil doseči upad ravni asparagina na serumsko koncentracijo 1 M.
The Provenge treatment process
Proces zdravljenja z zdravilom Provenge
The PSP is a validated clinician-rated scale that measures personal and social functioning in four domains: socially useful activities (e.g. work and study), personal and social relationships, self-care, and disturbing and aggressive behaviours.
Lestvica PSP je validirana lestvica, ki jo izpolni zdravnik, za merjenje osebnega in socialnega funkcioniranja na štirih področjih: socialno uporabne dejavnosti (npr. delo in študij), osebni in socialni odnosi, skrb zase ter moteče in agresivno vedenje.
The PSUR cycle for the medicinal product should follow a twice-yearly cycle until otherwise agreed by the CHMP.
Cikel PSUR za zdravilo mora slediti polletnemu ciklu dokler CHMP ne odloči drugače.
The PSUR cycle for the medicinal product should follow a yearly cycle until otherwise agreed by the CHMP.
Cikel PSUR za zdravilo mora slediti letnemu ciklu, dokler CHMP ne odloči drugače.
The PSUR cycle for the medicinal product should follow the standard requirements until otherwise agreed by the CHMP.
Cikel PSUR za zdravilo mora slediti standardnim zahtevam, dokler CHMP ne odloči drugače.
The PSUR cycle for the medicinal product should follow the standard requirements.
Cikel PSUR za zdravilo mora slediti standardnim zahtevam.
The PSUR cycle of Icandra will correspond to the one attributed to the cross-referred product, Eucreas, until otherwise specified.
Periode za predložitev periodičnih poročil o varnosti zdravila Icandra se bodo ujemale s periodami, ki so določene za referenčno zdravilo Eucreas, dokler ni zahtevano drugače.
The PSUR cycle of Jalra will correspond to the one attributed to the cross-referred product, Galvus, until otherwise specified.
Periode za predložitev periodičnih poročil o varnosti zdravila Jalra se bodo ujemale s periodami, ki so določene za referenčno zdravilo Galvus, dokler ni zahtevano drugače.
The PSUR cycle of Xiliarx will correspond to the one attributed to the cross-referred product, Galvus, until otherwise specified.
Periode za predložitev periodičnih poročil o varnosti zdravila Xiliarx se bodo ujemale s periodami, ki so določene za referenčno zdravilo Galvus, dokler ni zahtevano drugače.
The PSUR cycle of Zomarist will correspond to the one attributed to the cross-referred product, Eucreas, until otherwise specified.
Periode za predložitev periodičnih poročil o varnosti zdravila Zomarist se bodo ujemale s periodami, ki so določene za referenčno zdravilo Eucreas, dokler ni zahtevano drugače.
The PSUR submission schedule for Clopidogrel Teva Pharma film coated tablets should follow PSURs submission schedule for the reference medicinal product.
Razpored predložitve PSUR za Klopidogrel Teva Pharma filmsko obložene tablete se mora ujemati z razporedom predložitve PSUR za referenčno zdravilo.
The PSUR submission schedule for Raloxifene Teva should follow PSUR submission schedule for the reference medicinal product.
PSURi za zdravilo Raloksifen Teva morajo biti predloženi v skladu s časovnim razporedom za predložitev PSURov za referenčno zdravilo.
The PSUR submission schedule should follow the PSUR schedule for the reference medicinal product.
Razpored predlaganja PSUR-ov naj bo v skladu z razporedom predlaganja PSUR-ov za referenčno zdravilo.
The published studies showed that Crixivan boosted with ritonavir produced similar blood levels of indinavir to Crixivan taken without ritonavir.
Objavljene študije so pokazale, da jemanje zdravila Crixivan skupaj z ritonavirjem v krvi doseže podobne ravni indinavirja, kot če se zdravilo Crixivan jemlje brez ritonavirja.
The published study showed that patients taking combinations of medicines that included Xeloda survived for a similar length of time as those taking combinations including 5-FU.
Objavljena študija je pokazala, da so bolniki, ki so prejemali kombinacije zdravil, ki so vključevale zdravilo Xeloda, preživeli podobno dolgo časa kot bolniki, ki so jemali kombinacije s 5-FU.
The pump has a spray counter that clicks, so you can hear as well as see that the spray has been given and a protective cap.
Črpalka ima števec vpihov, ki slišno klika, tako da lahko ne samo vidite, ampak tudi slišite, da ste prejeli vpih, in zaščitno zaporko.
The pump has a spray counter that clicks, so you can hear as well as see that the spray has been given.
Črpalka ima števec vpihov, ki slišno klika, tako da lahko ne samo vidite, ampak tudi slišite, da ste prejeli vpih, in zaščitno zaporko.
The pump size and the number of sprays to be given are determined by the dog’s weight.
Velikost razpršilnika in število razprškov, ki jih je treba nanesti, sta odvisna od telesne mase psa.
The pump speed is adjusted according to the volume to be administered and the scheduled infusion time.
Hitrost črpalke prilagodite glede na volumen, ki ga želite uporabiti, in načrtovani čas infundiranja.
The pump tubing should be attached to the bag, the tubing purged and then capped.
Cevje črpalke je treba priključiti na vrečko, ga izprazniti in nato pokriti.
The purple 20 microgram Lyxumia pen must also be activated before use.
Tudi škrlatni peresnik Lyxumia 20 mikrogramov je treba pred uporabo aktivirati.
The purple pen contains 14 pre-set doses; each dose contains 20 micrograms of Lyxumia.
Škrlatni peresnik vsebuje 14 prednastavljenih odmerkov; vsak odmerek vsebuje 20 mikrogramov zdravila Lyxumia.
The purpose of the laboratory studies was to establish in piglets vaccinated at three weeks of age how long it took for piglets to be fully protected and the time protection lasts against PCV2 infection.
Namen laboratorijskih študij je bil ugotoviti, koliko časa preteče do vzpostavitve popolne zaščite in kako dolgo ta zaščita proti okužbi s cirkovirusom PCV2 traja pri pujskih, cepljenih pri starosti treh tednov.
The purpose of the patient alert card is to inform health care professionals of potential drug-drug interactions before any additional drug is prescribed.
Namen opozorilne kartice za bolnika je zdravnike obveščati o morebitnih interakcijah med zdravili, preden predpišejo katero koli dodatno zdravilo.
The purpose of the setup is to make sure that your Byetta pen is ready to use for the next 30 days.
Namen priprave je zagotovitev, da je vaš injekcijski peresnik Byetta pripravljen za odmerjanje za naslednjih 30 dni.
The purpose of the setup is to make sure that your Byetta pen is ready to use for the next 30 days.
Namen priprave je zagotovitev, da je vaš injekcijski peresnik ByettaA pripravljen za odmerjanje za naslednjih 30 dni.
The purpose of the study was to annually evaluate the durability of sustained virologic response (SVR) and assess the impact of continued viral negativity on clinical outcomes for patients who were sustained responders 24 weeks post-treatment with 24 or 48 weeks of peginterferon alfa-2b and ribavirin treatment.
Namen študije je bilo letno ocenjevanje trajanja trajnega virološkega odziva (SVR - sustained virologic response) in ugotavljanje vpliva nadaljnje virološke negativnosti na klinične izide pri bolnikih, ki so imeli trajen odziv 24 tednov po 24- ali 48-tedenskem zdravljenju s peginterferonom alfa- 2b in ribavirinom.
The purpose of these studies was to establish how long it took for pigs to be fully protected and the length of time protection lasts against PCV2 and Mycoplasma hyopneumoniae.
Namen teh študij je bilo ugotoviti, kdaj je nastopila popolna zaščita prašičev pred virusom PCV2 in bakterijo Mycoplasma hyopneumoniae in kako dolgo je ta zaščita trajala.
The purpose of these studies was to establish how long it took pigs to be fully protected and the length of time protection lasts against PCV2 and Mycoplasma hyopneumonia.
Namen teh študij je bil ugotoviti, po kolikem času je nastopila popolna zaščita prašičev pred PCV2 in bakterijo Mycoplasma hyopneumoniae in kako dolgo je ta zaščita trajala.
The push button scale tells you what dose has been set.
Merilna skala na pritisnem gumbu vam pove, kakšen odmerek je nastavljen.
The push button scale will show you the dose set (see Diagram N below).
Na merilni skali pritisnega gumba je viden nastavljeni odmerek (glejte sliko N spodaj).
The Pylobactell 13C-urea breath test kit contains a heat-sealed PET/aluminium foil/LDPE laminated sachet containing one Pylobactell tablet, six glass tubes with caps and bar code labels, three additional bar code labels, a 30 ml mixing and administration glass vial with cap, two straws, a package leaflet and an Analysis Request Form.
Set dihalnega testa Pylobactell s 13C-sečnino vsebuje zlepljeno laminirano vrečko iz polietilentereftalata/aluminijaste folije/polietilena majhne gostote z eno tableto Pylobactell, šest steklenih epruvet z zaporkami in etikete s črtnimi kodami, tri dodatne etikete s črtnimi kodami, 30 ml vialo za mešanje in aplikacijo z zaporko, dve slamici, navodilo za uporabo ter obrazec za naročilo analize.
The Pylobactell tablet is placed in the 30 ml mixing vial and water added to the marked line.
Tableto Pylobactell je treba dati v 30 ml vialo za mešanje ter dodati vodo do oznake.
The Pylobactell test is not expected to be harmful during pregnancy or to the health of the foetus / newborn child.
Ni pričakovati, da bi test Pylobactell imel škodljive učinke med nosečnostjo ali na zdravje zarodka / novorojenčka.
The QT interval prolongation potential of crizotinib was assessed in patients with either ALK-positive or ROS1-positive NSCLC who received crizotinib 250 mg twice daily.
Možnost, da krizotinib povzroči podaljšanje intervala QT, so ocenili pri bolnikih z ALK-pozitivnim ali ROS1-pozitivnim NSCLC, ki so jemali krizotinib v odmerku 250 mg dvakrat na dan.
The QT interval prolongation potential of Iclusig was assessed in 39 leukaemia patients who received 30 mg, 45 mg, or 60 mg Iclusig once daily.
Potencial zdravila Iclusig za podaljšanje intervala QT so ocenili pri 39 bolnikih z levkemijo, ki so prejemali 30 mg, 45 mg ali 60 mg zdravila Iclusig enkrat na dan.
The quantity of Cuprymina required for radiolabelling and the quantity of 64Cu-labelled medicinal product that is subsequently administered will depend on the medicinal product radiolabelled and its intended use.
Količina radiofarmacevtskega predhodnika Cuprymina, potrebna za radioaktivno označevanje, in količina z bakrom (64Cu) označenega zdravila, ki je nato uporabljena, bo odvisna od radioaktivno označenega zdravila in njegove načrtovane uporabe.
The quantity of EndolucinBeta required for radiolabelling and the quantity of Lutetium (177Lu)- labelled medicinal product that is subsequently administered will depend on the medicinal product radiolabelled and its intended use.
Količina radionuklidnega predhodnika EndolucinBeta, potrebna za radioaktivno označevanje, in količina z lutecijem (177Lu) označenega zdravila, ki je nato uporabljeno, sta odvisni od radioaktivno označenega zdravila in njegove predvidene uporabe.
The quantity of EVARREST to be applied and the frequency of application should always be dictated by the underlying clinical needs of the patient.
Količina zdravila EVARREST, ki ga boste nanesli, in pogostost nanosa morata vedno ustrezati osnovnim kliničnim potrebam bolnika.
The quantity to be administered usually recommended for an adult ranges is 300 MBq (megabecquerel, the unit used to express radioactivity).
Količina, ki se običajno priporoča za odraslega, je 300 MBq (megabecquerel, enota za izražanje radioaktivnosti).
The Qutenza cutaneous patch should be applied by a physician or by a health care professional under the supervision of a physician.
Dermalni obliž Qutenza mora aplicirati zdravnik ali zdravstveni delavec pod nadzorom zdravnika.
The Qutenza patch is stored in a paper coated aluminium foil sachet with acrylnitrile-acrylic acid copolymer heat seal layer.
Obliž Qutenza se nahaja v vrečki iz s papirjem kaširane aluminijaste folije s toplotno varljivo plastjo iz akrilniltrila-akrilester kopolimera.
The R-isomer of oxybutynin shows greater selectivity for the M1 and M3 muscarinic subtypes (predominant in bladder detrusor muscle and parotid gland) compared to the M2 subtype (predominant in cardiac tissue).
R-izomera oksibutinina je bolj selektivna za muskarinska podtipa M1 in M3 (ki prevladujeta v detruzorski mišici v sečnem mehurju in parotidni žlezi) kot za podtip M2 (ki prevladuje v srčnem tkivu).
The race distribution of subjects was as follows: 82% White,
Porazdelitev preiskovancev po rasah je bila naslednja: 82 % belcev, 18 % ne-belcev, 14 % črncev,
The radiation dose from 18FDG-PET (Fluorodeoxyglucose – Positron Emission Tomography) is lower than that from NeoSpect, whilst still achieving high sensitivity and specificity.
Doza sevanja je pri 18FDG-PET (Fluorodeoksiglukoza - pozitron emisijska tomografija) nižji kot pri NeoSpectu, ob ohranjeni visoki občutljivosti in specifičnosti.
The radiation dose received by the various organs following administration of a Yttrium (90Y)- labelled medicinal product will be dependent on the specific pharmaceutical being radiolabelled.
Doze sevanja, ki so jim izpostavljeni razni organi po aplikaciji z itrijem (90Y) označenega zdravila, so odvisne od vrste zdravila, ki ga označujemo.
The radiation dose received by the various organs following intravenous administration of a 64Cu- labelled medicinal product is dependent on the specific molecule being radiolabelled.
Odmerek sevanja, ki ga prejmejo različni organi po intravenskem dajanju z bakrom (64Cu) označenega zdravila, je odvisen od posameznega zdravila, ki je bilo radioaktivno označeno.
The radiation dose received by the various organs following intravenous administration of an Yttrium (90Y)-labelled medicinal product is dependent on the specific medicinal product being radiolabelled.
Prejete doze sevanja, ki ga prejmejo različni organi po intravenskem dajanju z itrijem (90Y) označenega zdravila, so odvisne od specifičnega zdravila, ki se radioaktivno označuje.
The radiation dose received by various organs following intravenous administration of a Lutetium (177Lu)- labelled medicinal product is dependent on the specific molecule being radiolabelled.
Odmerki sevanja, ki jih prejmejo različni organi po intravenskem dajanju z lutecijem (177Lu) označenega zdravila, so odvisni od posamezne molekule, ki se radioaktivno označuje.
The radiographic response of subcutaneous administered tocilizumab was assessed in a double-blind, controlled, multicenter study in patients with active RA (SC-II).
V dvojno slepi, kontrolirani, multicentrični študiji pri bolnikih z aktivnim revmatoidnim artritisom (SC-II) so radiološko ocenjevali subkutano dani tocilizumab.
The radioincorporation assay for radiochemical purity, is performed by Instant Thin Layer Chromatography (ITLC) and must be carried out according to the following procedure.
Radiokemijsko čistoto določamo s tenkoplastno kromatografijo hitre izvedbe (ITLC – Instant Thin Layer Chromatography) po naslednjem postopku:
The radiolabelled medicine is then given to the patient according to the instructions in that medicine’s product information.
Nato bolnik prejme radioaktivno označeno zdravilo v skladu z navodili iz informacij o označenem zdravilu.
The radiolabelled medicine is then given to the patient according to the instructions in that medicine’s product information.
Nato bolnik prejme radiooznačeno zdravilo v skladu z navodili iz informacij o označenem zdravilu.